Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A Phase III, Randomized, Open-Label, Multi-center Study of SHR-1210(Anti-PD-1 Antibody) in Combination With Pemetrexed and Carboplatin as First Line Therapy in Subjects With Advanced/Metastatic Non-squamous Non-small Cell Lung Cancer

Next Previous
Trial Profile

A Phase III, Randomized, Open-Label, Multi-center Study of SHR-1210(Anti-PD-1 Antibody) in Combination With Pemetrexed and Carboplatin as First Line Therapy in Subjects With Advanced/Metastatic Non-squamous Non-small Cell Lung Cancer

Status: Completed
Phase of Trial: Phase III

Latest Information Update: 05 Nov 2021

Price :
$35 *
Note:
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Camrelizumab (Primary) ; Carboplatin; Pemetrexed
  • Indications Carcinoma; Non-small cell lung cancer
  • Focus Therapeutic Use
  • Sponsors Jiangsu Hengrui Medicine Co.

Most Recent Events

  • 31 Jan 2021 Results (Data cut off 25 Jan 2020, median follow up duration 19.3 months) assessing OS and PFS2 (time to second progression) based on long-term follow-up, presented at the 2020 World Conference on Lung Cancer.
  • 07 Jun 2020 Status changed from recruiting to completed.
  • 10 Sep 2019 Interim analysis on efficacy and safety of camrelizumab plus carboplatin/pemetrexed as 1st line treatment in Chinese advanced/metastatic non-squamous NSCLC patients presented at the 20th World Conference on Lung Cancer

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top